Pulmonary Arterial Hypertension

The podcast addresses pulmonary arterial hypertension (PAH), a condition involving increased pulmonary artery pressure due to imbalances in vasoconstrictors and vasodilators. It requires right heart catheterization for diagnosis, with specific pressure measurements. The discussion covers the five classifications of PAH, ranging from idiopathic causes to those related to heart or lung disease, and the importance of screening high-risk patients. Treatment goals focus on symptom alleviation and improved quality of life, with therapies targeting vasodilation, vasoconstriction inhibition, and thrombosis risk reduction. The speakers review various treatment options, including prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, guanylate cyclase stimulants, and prostacyclin receptor agonists, also noting the importance of supportive therapies like anticoagulants and diuretics. New guidelines favor initial combination therapy with ambrisentan and tadalafil for certain functional classes.